Clinical trial
A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic β Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
NCT05743244 is registered in ClinicalTrials.gov with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subtype-Selective JAK Inhibitors for Preservation of Pancreatic β Cell Function in Newly Diagnosed Type 1 Diabetes Mellitus
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- October 19, 2023
- Completion date
- October 30, 2027
- Enrollment
- 78 (estimated)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.